Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition

No Revlimid Sales In Q2

 
• By Vibha Ravi
  
M&As As Part Of Growth Strategy
Acquisitions Are Part Of Zydus' Specialty Growth Strategy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip